CMBA
ACHN

C.M. Bidwell & Associates’s Achillion Pharmaceuticals ACHN Stock Holding History

C.M. Bidwell & Associates’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-20,825
Closed -$77K – 473
2018
Q1 		$77K Buy
+20,825
New +$68.2K 0.07% 218

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

C.M. Bidwell & Associates's ACHN Position: Q2 2018 in Review

C.M. Bidwell & Associates sold out of Achillion Pharmaceuticals (ACHN) in Q2 2018, closing a stake of 20,825 shares — an estimated $77K sold.

C.M. Bidwell & Associates first reported a position in ACHN in Q1 2018 and held it in 1 quarter. The position peaked at $77K in Q1 2018. 124 funds tracked by Wall St. Rank hold ACHN as of Q2 2018.

  • C.M. Bidwell & Associates reported no remaining Achillion Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 20,825 Achillion Pharmaceuticals shares in Q2 2018, an estimated $77K.
  • C.M. Bidwell & Associates first reported a position in Achillion Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • C.M. Bidwell & Associates's Achillion Pharmaceuticals position peaked at $77K in Q1 2018.
  • 124 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2018.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2018, filed 13 Aug 2018.